23andMe's New DNA Test Restores Some Health Analysis for $199
- Startup unveils latest kit after FDA halted sales in 2013
- Revamped screening service covers 36 genetic disorders
This article is for subscribers only.
Genetic testing company 23andMe Inc. has restored some health analysis to its latest DNA screening kit, ending a two-year hiatus after a standoff with U.S. regulators.
The Silicon Valley firm, which recently raised $115 million in venture-capital funding at a valuation of $1.1 billion, introduced its redesigned personal genome service on Wednesday. The kit brings together ancestry analysis with reports on physical traits such as baldness or freckles, health conditions such as lactose intolerance and whether the consumer carries genetic mutations associated with certain disorders. The service costs $199, double the previous $99 price tag.